Malaysian PM to visit Qatar, UAE from March 27 to 31

PUTRAJAYA Malaysian Prime Minister Ismail Sabri Yaakob will undertake his first official visits to Qatar and the United Arab Emirates (UAE) starting Sunday until March 31.

According to the Foreign Ministry, during his visit to Qatar, Ismail Sabri will have an audience with the Amir of Qatar, Sheikh Tamim bin Hamad Al Thani.

“Strengthening of Malaysia-Qatar long-standing and multifaceted cooperation will be high on agenda,” the ministry said in a statement Saturday.

Foreign Ministry said the leaders will chart a way forward in economic collaboration and other post-pandemic recovery efforts as well as exchange views on international issues of mutual concern.

In the United Arab Emirates, Ismail Sabri will hold a meeting with the Vice-President and Prime Minister of the UAE and Ruler of Dubai, Sheikh Mohammed bin Rashid Al Maktoum.

“The leaders will take stock of the expanding multifaceted cooperation between the two countries, including in addressing COVID-19 pandemic and promoting further post-pandemic recovery efforts,” said the statement, adding that the leaders will also exchange views on international issues of mutual concern.

Ismail Sabri will also have programmes at Expo 2020 Dubai, including a visit to the Malaysia Pavilion.

The visits will be subjected to strict COVID-19 preventative standard operating procedures put in place by Malaysia, Qatar and the UAE.

Source: Nam News Network

Rich Countries Getting New COVID Vaccine Before Poorer Ones

The company behind a COVID-19 vaccine touted as a key tool for the developing world has sent tens of millions of doses to wealthy nations but provided none yet to the U.N.-backed effort to supply poorer countries, a sign that inequity persists in the global response to the pandemic.

A quarter-million doses from the company were supposed to be available to the vaccine-sharing initiative, called COVAX, by March. But the U.N. agency in charge of deliveries says the first shipments now likely won’t be made until April or May.

It wasn’t supposed to be this way. The company, Novavax, got $388 million from one of the organizations leading COVAX to fast-track the vaccine’s development and help make the shot available in poorer countries.

The investment guaranteed COVAX the “right of first refusal” to the first Novavax doses, but the deal applied only to factories in the Czech Republic, South Korea and Spain, said Bjorg Dystvold Nilsson, spokesman for COVAX co-founder CEPI.

There are other factories that aren’t part of the deal — and their shots are going elsewhere.

The Serum Institute of India, the world’s largest vaccine maker, has manufactured millions of Novavax doses. According to India’s Ministry of External Affairs and the institute, more than 28.9 million of those doses were sent to the Netherlands in January and February, while Australia received about 6 million doses. Indonesia also received about 9 million doses in December.

Thousands of other Novavax doses were also shipped from a Netherlands factory to other EU countries.

“Whatever the reason, a vaccine that was believed to be highly suitable for poor countries is now in large part going to rich countries,” said Zain Rizvi, a drug policy expert at the U.S. advocacy group Public Citizen. “It’s tragic that in year three of the pandemic, we still cannot get the resources, attention and political will to solve vaccine inequity.”

The delay is the latest setback for COVAX, which has been repeatedly hit by supply problems and has missed numerous targets to share doses.

Last year, WHO Director-General Tedros Adhanom Ghebreyesus decried the chasm in vaccine supplies between rich and poor countries as a “catastrophic moral failure.”

Problems linger

Vaccine availability has been improving in poorer regions recently, but logistical problems persist.

According to data from Oxford University, only about 14% of people in low-income countries have received at least one dose of COVID-19 vaccine. More than 680 million doses of COVAX-provided vaccines remain unused or have expired, according to government data.

Even with vaccine supplies improving, some officials were eagerly awaiting the Novavax vaccine in particular because it is easier to transport and store than some other coronavirus shots. They also hoped it might be more enticing to people skeptical of the AstraZeneca vaccine, which suffered through a botched rollout in Europe.

Countries including Zimbabwe, the Central African Republic and Kiribati were among those in line to be offered Novavax doses by March from COVAX.

Before the pandemic, Novavax was a small American company that had never brought any vaccine to market. Its shots have proven highly effective, but it is relying heavily on other companies to make them.

The company, struggling to scale up production, also has delayed delivery to other countries, including some in the European Union. COVAX is supposed to receive more than 1 billion Novavax doses.

In a statement, the Gaithersburg, Maryland, company acknowledged that it had yet to share any shots with Gavi, the Vaccine Alliance, which fronts the COVAX effort, but said it stands ready to do so.

“We continue to work with Gavi to reach our shared goal of ensuring global access to our protein-based vaccine where it is needed most,” Novavax said.

Gavi suggested part of the delay is that the Novavax vaccine wasn’t authorized by WHO until December. Gavi said it planned to allocate Novavax in the future and was “in close touch with the manufacturer and expects the supply to be available for delivery when countries need it.”

Less urgency

Health officials also worry that the urgency to vaccinate people everywhere against COVID-19 has disappeared — especially as many countries roll back precautions and the world’s attention is diverted.

“Rich countries have moved on from COVID, and everyone is fixated on the war in Ukraine, but COVID-19 remains an acute crisis for most people in the world,” said Ritu Sharma, a vice president at the charity CARE.

She said COVAX was still desperately short of vaccines and that based on the current pace of vaccination, the world was still “years and years” away from immunizing enough people to stop future COVID-19 waves.

Other experts said it was incumbent on public health agencies to ensure their investments in vaccines would benefit poor countries and to be more transparent about what went wrong.

“Whatever the explanation is, it’s unsatisfactory,” said Brook Baker, an access-to-medicines specialist at Northeastern University. “The bottom line is that there are still a lot of unvaccinated people in poor countries, and once again, they are at the back of the line.”

Source: Voice of America

Vietnam Reports 108,979 New COVID-19 Cases

HANOI, Vietnam reported 108,979 new COVID-19 cases yesterday, down 11,021 cases from Thursday, according to its Ministry of Health.

The new infections, logged in 62 localities nationwide, included 108,957 domestically transmitted and 22 imported.

The Vietnamese capital, Hanoi, remained the pandemic hotspot with 10,803 new cases yesterday, followed by northern Phu Tho province with 4,555, and central Nghe An province with 4,023.

On the same day, health authorities also documented 52,522 COVID-19 cases detected earlier in three northern localities of Hoa Binh, Bac Giang, and Vinh Phuc.

The infections brought the country’s total tally to 8,761,252, with 42,196 deaths. Nationwide, 5,001,564 COVID-19 patients, or 57 percent of the infections, have so far recovered.

Nearly 204.6 million doses of COVID-19 vaccines have been administered in the country, including 187.4 million shots among people aged 18 and above, said the ministry.

Vietnam has by far gone through four waves of increasing scale, complication, and infectivity. As of yesterday, it has registered over 8.75 million locally transmitted COVID-19 cases, since the start of the current wave in Apr, 2021, said the health ministry.

Source: Nam News Network

Singapore Reports 7,584 New COVID-19 Cases

SINGAPORE, Singapore reported 7,584 new confirmed cases of COVID-19 yesterday, bringing the total tally to 1,060,723.

Of the new cases, 1,061 cases were detected through PCR (polymerase chain reaction) tests, and 6,315 through ART (antigen rapid test) tests, according to statistics released by the Ministry of Health.

Among the new cases, 7,376 were local transmissions and 208 were imported cases.

A total of 826 cases are currently warded in hospitals, with 28 cases in intensive care units.

In addition, 13 deaths were reported from COVID-19 yesterday, bringing the total death toll to 1,239, the ministry said.

Source: Nam News Network

Indonesia Reports 4,857 New COVID-19 Cases, 120 More Deaths

JAKARTA, Indonesia yesterday confirmed 4,857 new COVID-19 cases, taking its tally of infections to 5,991,687, the country’s Health Ministry said.

According to the ministry, the death toll from COVID-19 rose by 120 to 154,463, and 14,710 more people have recovered from the disease, bringing the total number of recoveries to 5,691,220.

As the Indonesian government is accelerating its national vaccination programmes, to curb the spread of the virus, more than 195.53 million people have received their first dose of COVID-19 vaccines, while over 156.63 million have taken their second doses.

Indonesia started mass COVID-19 vaccinations in Jan last year, after authorities approved the emergency use of the Chinese Sinovac vaccine.

Aiming to fully vaccinate 208.26 million people in the country, the government has administered over 370.56 million vaccine doses so far, including the third booster jabs.

Source: Nam News Network

Costs of Going Unvaccinated in America Mounting for Workers, Companies

Nearly a year after COVID vaccines became freely available in the U.S., one fourth of American adults remain unvaccinated, and a picture of the economic cost of vaccine hesitancy is emerging. It points to financial risk for individuals, companies and publicly funded programs.

Vaccine hesitancy likely already accounts for tens of billions of dollars in preventable U.S. hospitalization costs and up to hundreds of thousands of preventable deaths, say public health experts.

For individuals forgoing vaccination, the risks can include layoffs and ineligibility to collect unemployment, higher insurance premiums, growing out-of-pocket medical costs or loss of academic scholarships.

For employers, vaccine hesitancy can contribute to short-staffed workplaces. For taxpayers, it could mean a financial drain on programs such as Medicare, which provides health care for seniors.

Some employers are looking to pass along a risk premium to unvaccinated workers, not unlike how smokers can be required to pay higher health premiums. One airline said it will charge unvaccinated workers $200 extra a month in insurance.

“When the vaccines emerged it seemed like everyone wanted one and the big question was how long it would take to meet the demand,” said Kosali Simon, a professor of health economics at Indiana University. “It didn’t occur to me that, a year later, we’d be studying the cost of people not wanting the vaccines.”

Alicia Royce, a 38-year-old special education teacher in Coachella, California, opted out of getting the COVID vaccine or having her two vaccine-eligible children get it. Royce’s parents got the shots, but she has been concerned by issues including reports of adverse reactions.

The decision puts Royce in a delicate spot. Her school, like others in California, began a vaccine mandate for staff last year. For now, Royce has a religious exemption and gets tested for COVID twice a week before entering the classroom. The situation has prompted her family to plan a move to Alabama, where schools have not imposed mandates, after the school year.

“I’ll get paid less,” said Royce, who expects to take a $40,000-a-year pay cut. “But I’m moving for my own personal freedom to choose.”

Preventable care, billions in costs

As the pandemic enters its third year, the number of U.S. patients hospitalized with COVID is near a 17-month low. Most Americans are vaccinated, and the country is regaining a semblance of normalcy, even as authorities predict a coming uptick in infections from the BA.2 sub-variant.

Yet as millions return to offices, public transportation and other social settings, Centers for Disease Control and Prevention figures show nearly 25% of U.S. adults haven’t been fully vaccinated, and the latest data suggests many holdouts won’t be easily swayed: The number of people seeking a first COVID vaccine in the U.S. has fallen to 14-month lows.

Vaccines have proven to be a powerful tool against the virus. CDC figures from 2021’s Delta wave found that unvaccinated Americans had four times greater risk of being infected, and nearly 13 times higher risk of death from COVID. The disparities were even greater for those who received booster shots, who were 53 times less likely to die from COVID. Less than half of the country’s vaccinated population has so far received a booster.

In a December study, the nonprofit Kaiser Family Foundation, which tracks U.S. health policy and outcomes, estimated that between June and November of 2021, unvaccinated American adults accounted for $13.8 billion in “preventable” COVID hospitalization costs nationwide.

Kaiser estimated that over that six-month period, which included the Delta wave, vaccinations could have averted 59% of COVID hospitalizations among U.S. adults. Kaiser tallied 690,000 vaccine-preventable hospitalizations, at an average cost of $20,000. And it estimated vaccinations could have prevented 163,000 U.S. deaths over the same period.

If vaccine hesitancy accounted for half of the more than 1 million new U.S. COVID hospitalizations since December, the added cost of preventable hospital stays could amount to another $10 billion, Reuters found.

One thing is clear: As U.S. insurance providers and hospital networks reckon with vaccine hesitancy, it’s likely that patients hospitalized for COVID will end up shouldering a bigger portion of the bill.

“These hospitalizations are not only devastating for patients and their families but could also put patients on the hook for thousands of dollars,” Krutika Amin, a Kaiser associate director and one of the December study’s co-authors, told Reuters. Unlike earlier in the pandemic, Amin said, most private health insurers have stopped waiving cost-sharing or deductibles for COVID patients who end up hospitalized.

For some insurance plans, the cost to a hospitalized COVID patient can exceed $8,000 just for “in-network” services, she added. The expenses could balloon for the uninsured and those turning to out-of-network care.

Now that Americans have the choice to protect themselves with vaccines, insurance companies are requiring patients to bear more of these costs, but “many people do not have enough money to pay,” Amin said.

More recent data – covering the Omicron wave – underscores the risk for the unvaccinated. During January in New York State, unvaccinated adults were more than 13 times as likely to be hospitalized with COVID than fully vaccinated adults, state health department figues show.

Political flashpoint

The U.S. has spent billions to get vaccine shots into arms, including more than $19.3 billion to help develop vaccines, federal reports show.

Still, the United States has one of the largest COVID vaccine holdout rates among highly developed countries, as some question the need for getting the shots or bristle at government or workplace mandates.

“The subset of the population that is really anti-COVID vaccine, ready to quit jobs or test in order to go to work, is now pretty hardened,” said Julie Downs, a social psychology professor at Carnegie Mellon University.

COVID vaccines have become a political flashpoint, and vaccination rates vary widely by region: In Vermont, public health data shows 84% of those 18 and up are fully vaccinated, while the rate is just above 60% in Alabama.

Nearly 76% of people in the United States have had at least one dose of a COVID vaccine, CDC data shows, but the fully vaccinated figure – across all age-groups – stands at 64%. The Food and Drug Administration hasn’t yet approved a COVID vaccine for children under 5.

Perhaps the biggest financial risk vaccine holdouts have faced is getting laid off from their jobs, said Kaiser’s Amin.

New York City, which requires city workers to be vaccinated, fired more than 1,400 of them last month who hadn’t received a vaccine shot by the city’s deadline, while around 9,000 other workers remained in the process of seeking exemptions to the requirement, city figures show. The vast majority of the city’s 370,000-person workforce is vaccinated.

A Kaiser Family Foundation nationwide survey in October found that about a quarter of workers said their employer required proof of vaccination. Only 1% of workers surveyed — and 5% of unvaccinated workers — reported having left a job due to a workplace vaccine mandate.

A tiny minority of healthcare workers across the country have been fired or placed on work leave because they chose to remain unvaccinated, but the dismissals still amount to thousands of layoffs, according to a report from Fierce Healthcare, which tracks the trend.

No-vax tax

Giant employers including J.P. Morgan and Bank of America have informed their U.S. employees they can expect to pay more – or receive fewer perks through company wellness programs – if they don’t provide proof of vaccination.

Other companies have extended an insurance premium surcharge for unvaccinated spouses or family members of employees if they want to be insured as a dependent under an employee’s health plan.

And after global life insurance providers were hit with a higher-than-expected $5.5 billion in claims during the first nine months of 2021, insurers will be looking to calibrate premiums more closely to COVID mortality risks going forward, Reuters reported.

Vaccination status and other health risks – such as obesity or smoking — are metrics life insurers can probe when customers seek coverage. Under the U.S. Affordable Care Act, individuals seeking health insurance can’t be denied for pre-existing conditions, including COVID, or charged more for not being vaccinated. But companies who cover some of employees’ health insurance costs can pass along higher costs to unvaccinated employees.

Delta Airlines said last year it would charge employees who didn’t vaccinate an extra $200 a month for health insurance. The airline said the extra charge reflected the higher risk of COVID hospitalization for those employees, and noted that employee hospitalizations for COVID had cost $50,000 each so far, on average.

University students also can face financial consequences for opting out. At least 500 U.S. colleges have vaccine mandates, some barring enrollment or in-person schooling for those who don’t comply, or requiring them to undergo frequent COVID testing.

Cait Corrigan said she enrolled in a master’s program in theology at Boston University this year and was offered an academic scholarship. Corrigan, who has led public-activism efforts against vaccine mandates, said she got a religious exemption to the school’s vaccine mandate, but the school required that she take regular nasal swab tests to attend. Corrigan said she declined to submit to nasal tests for “medical reasons.”

The university suspended her and withdrew funding, she said. “It was a big loss.” Boston University didn’t respond to a request for comment.

Now in New York, Corrigan says she is campaigning for a congressional seat as a Republican. Her platform: “medical freedom.”

Source: Voice of America